disease interaction(s) of diabetes mellitus type-2 with cirrhosis
Jump to navigation
Jump to search
Management
- GLP-1 receptor agonist treatmment of diabetes mellitus type-2 lowers risk of steatosis progression to cirrhosis & mortality[1]
- SGLT-2 inhibitors reduce risk for end-stage kidney disease, acute kidney injury major adverse cardiovascular events, hepatic decompensation & mortality in patients with diabetes mellitus type-2 & cirrhosis[2]
More general terms
References
- ↑ 1.0 1.1 Kanwal F et al. GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. JAMA Intern Med 2024 Sep 16; PMID: https://pubmed.ncbi.nlm.nih.gov/39283612 PMCID: PMC11406452 (available on 2025-09-16) https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2823685
- ↑ 2.0 2.1 Chung MC, Yu TM, Wu LY, Wu MJ, Shieh JJ, Chung CJ. SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis. JAMA Netw Open. 2026 Feb 2;9(2):e2560429. PMID: https://pubmed.ncbi.nlm.nih.gov/41729519 PMCID: PMC12930281 Free PMC article. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2845333